Literature DB >> 9539774

Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a).

D A Sanan1, D L Newland, R Tao, S Marcovina, J Wang, V Mooser, R E Hammer, H H Hobbs.   

Abstract

We have generated mice with markedly elevated plasma levels of human low density lipoprotein (LDL) and reduced plasma levels of high density lipoprotein. These mice have no functional LDL receptors [LDLR-/-] and express a human apolipoprotein B-100 (apoB) transgene [Tg(apoB+/+)] with or without an apo(a) transgene [Tg(apoa+/-)]. Twenty animals (10 males and 10 females) of each of the following four genotypes were maintained on a chow diet: (i) LDLR-/-, (ii) LDLR-/-;Tg(apoa+/-), (iii) LDLR-/-;Tg(apoB+/+), and (iv)LDLR-/-;Tg(apoB+/+);Tg(apo+/-). The mice were killed at 6 mo, and the percent area of the aortic intimal surface that stained positive for neutral lipid was quantified. Mean percent areas of lipid staining were not significantly different between the LDLR-/- and LDLR-/-;Tg(apoa+/-) mice (1.0 +/- 0.2% vs. 1.4 +/- 0.3%). However, the LDLR-/-;Tg(apoB+/+) mice had approximately 15-fold greater mean lesion area than the LDLR-/- mice. No significant difference was found in percent lesion area in the LDLR-/-;Tg(apoB+/+) mice whether or not they expressed apo(a) [18.5 +/- 2.5%, without lipoprotein(a), Lp(a), vs. 16.0 +/- 1.7%, with Lp(a)]. Histochemical analyses of the sections from the proximal aorta of LDLR-/-;Tg(apoB+/+) mice revealed large, complex, lipid-laden atherosclerotic lesions that stained intensely with human apoB-100 antibodies. In mice expressing Lp(a), large amounts of apo(a) protein colocalized with apoB-100 in the lesions. We conclude that LDLR-/-; Tg(apoB+/+) mice exhibit accelerated atherosclerosis on a chow diet and thus provide an excellent animal model in which to study atherosclerosis. We found no evidence that apo(a) increased atherosclerosis in this animal model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9539774      PMCID: PMC22526          DOI: 10.1073/pnas.95.8.4544

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice.

Authors:  S Ishibashi; J L Goldstein; M S Brown; J Herz; D K Burns
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

2.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.

Authors:  Y Nakashima; A S Plump; E W Raines; J L Breslow; R Ross
Journal:  Arterioscler Thromb       Date:  1994-01

3.  Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression.

Authors:  R L Reddick; S H Zhang; N Maeda
Journal:  Arterioscler Thromb       Date:  1994-01

4.  Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption.

Authors:  S H Zhang; R L Reddick; B Burkey; N Maeda
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

5.  Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice.

Authors:  A C Liu; R M Lawn; J G Verstuyft; E M Rubin
Journal:  J Lipid Res       Date:  1994-12       Impact factor: 5.922

6.  International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material.

Authors:  S M Marcovina; J J Albers; H Kennedy; J V Mei; L O Henderson; W H Hannon
Journal:  Clin Chem       Date:  1994-04       Impact factor: 8.327

7.  Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice.

Authors:  D J Grainger; P R Kemp; A C Liu; R M Lawn; J C Metcalfe
Journal:  Nature       Date:  1994-08-11       Impact factor: 49.962

8.  Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice.

Authors:  C Pászty; N Maeda; J Verstuyft; E M Rubin
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

9.  Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse.

Authors:  A S Plump; C J Scott; J L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

10.  Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet.

Authors:  D A Purcell-Huynh; R V Farese; D F Johnson; L M Flynn; V Pierotti; D L Newland; M F Linton; D A Sanan; S G Young
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

View more
  39 in total

Review 1.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

2.  Calcific aortic stenosis: a disease ready for prime time.

Authors:  Nalini M Rajamannan
Journal:  Circulation       Date:  2006-11-07       Impact factor: 29.690

3.  Aggressive very low-density lipoprotein (VLDL) and LDL lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficient mice.

Authors:  Erin D MacDougall; Farah Kramer; Patti Polinsky; Shelley Barnhart; Bardia Askari; Fredrik Johansson; Rebecca Varon; Michael E Rosenfeld; Kazuhiro Oka; Lawrence Chan; Stephen M Schwartz; Karin E Bornfeldt
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

4.  Nonclinical Pharmacology/Toxicology Study of AAV8.TBG.mLDLR and AAV8.TBG.hLDLR in a Mouse Model of Homozygous Familial Hypercholesterolemia.

Authors:  Jenny A Greig; Maria P Limberis; Peter Bell; Shu-Jen Chen; Roberto Calcedo; Daniel J Rader; James M Wilson
Journal:  Hum Gene Ther Clin Dev       Date:  2017-03       Impact factor: 5.032

5.  Catechin prevents severe dyslipidemia-associated changes in wall biomechanics of cerebral arteries in LDLr-/-:hApoB+/+ mice and improves cerebral blood flow.

Authors:  Virginie Bolduc; Edward Baraghis; Natacha Duquette; Nathalie Thorin-Trescases; Jean Lambert; Frédéric Lesage; Eric Thorin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-20       Impact factor: 4.733

6.  Up-regulation of thromboxane A₂ impairs cerebrovascular eNOS function in aging atherosclerotic mice.

Authors:  Annick Drouin; Nada Farhat; Virginie Bolduc; Nathalie Thorin-Trescases; Marc-Antoine Gillis; Louis Villeneuve; Albert Nguyen; Eric Thorin
Journal:  Pflugers Arch       Date:  2011-05-27       Impact factor: 3.657

7.  Compared with saturated fatty acids, dietary monounsaturated fatty acids and carbohydrates increase atherosclerosis and VLDL cholesterol levels in LDL receptor-deficient, but not apolipoprotein E-deficient, mice.

Authors:  M Merkel; W Velez-Carrasco; L C Hudgins; J L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

Review 8.  Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications.

Authors:  Angelo M Scanu
Journal:  Curr Atheroscler Rep       Date:  2003-03       Impact factor: 5.113

9.  Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol.

Authors:  Liqing Yu; Jia Li-Hawkins; Robert E Hammer; Knut E Berge; Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

10.  Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis.

Authors:  Sadik H Kassim; Hui Li; Luk H Vandenberghe; Christian Hinderer; Peter Bell; Dawn Marchadier; Aisha Wilson; Debra Cromley; Valeska Redon; Hongwei Yu; James M Wilson; Daniel J Rader
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.